Month: September 2026

NORWICH, N.Y., Sept. 21, 2026 (GLOBE NEWSWIRE) — NBT Bancorp Inc. (“NBT” or the “Company”) (NASDAQ: NBTB) announced today that Kimberly A. Boynton will join the Boards of Directors of NBT Bancorp Inc. and NBT Bank, N.A. on October 1, 2026. Boynton is the former President and Chief Executive Officer of Crouse Health and is currently a licensed real estate salesperson with Cushman & Wakefield | Pyramid Brokerage Company, where she specializes in office and industrial real estate throughout the Syracuse market.

“We are pleased to welcome Kimberly to the NBT Board of Directors,” said NBT Board Chair Martin A. Dietrich. “Kimberly’s career spans executive leadership in healthcare, financial management, board governance and commercial real estate. That breadth of experience, combined with her deep understanding of the Central New York business community and regional economy, will bring valuable perspective to our Board and the work we do on behalf of our shareholders, customers and communities.”

Boynton spent nearly 25 years with Crouse Health, serving as President and Chief Executive Officer from January 2014 until March 2023 and as Vice President of the Crouse Health Foundation. Prior to her appointment as Chief Executive Officer, she served as Chief Financial Officer, helping to lead the organization’s financial strategy and operational management. Throughout her tenure at Crouse Health, Boynton led strategic growth initiatives, physician practice acquisitions and major capital projects while overseeing a broad range of operational functions across the organization.

Prior to joining Crouse Health, Boynton worked in public accounting with Coopers & Lybrand, where she developed expertise in financial reporting, auditing and client advisory services.

Boynton has extensive experience serving on boards. She is currently Vice Chairperson of the Board of Trustees of SRC, Inc. and serves on the boards of AAA Western and Central New York, Byrne Dairy, Inc. and NYSTEC. She has been actively involved in numerous civic and nonprofit organizations throughout Central New York. Boynton earned a Bachelor of Business Administration in Accounting from Niagara University and an MBA from Syracuse University’s Martin J. Whitman School of Management.

About NBT Bancorp Inc. and NBT Bank, N.A.
NBT Bancorp Inc. is a financial holding company headquartered in Norwich, NY, with total assets of $16.21 billion at June 30, 2026. The Company primarily operates through NBT Bank, N.A., a full-service community bank, and through two financial services companies. NBT Bank, N.A. has 174 banking locations in New York, Pennsylvania, Vermont, Massachusetts, New Hampshire, Maine and Connecticut. EPIC Retirement Plan Services, based in Rochester, NY, is a national benefits administration firm. NBT Insurance Agency, LLC, based in Norwich, NY, is a full-service regional insurance agency. More information about NBT and its divisions is available online at: www.nbtbancorp.com, www.nbtbank.com, www.epicrps.com and www.nbtbank.com/insurance.

CONTACT:
Florence Doller
SVP & Director of Corporate Communications
607.337.6118 | fdoller@nbtbank.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08c02048-af8b-4377-9e58-8b30c212b2b7

This press release was published by a CLEAR® Verified individual.

Landry Brings Two Decades of Medtech and Public Company Finance Experience

MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced. Mr. Landry will join the Company on October 12, 2026, and assume the CFO role on the day after the Company files its Form 10-Q for the quarter ending September 30, 2026.   Mr. Oasheim will remain with the Company for a transition period consistent with his previously disclosed transition agreement.

“John is exactly the kind of finance leader we need for this next chapter,” said Kevin Hykes, President and CEO of CVRx. “Over the past two decades, he has played a key role in building and financing high growth medical device companies introducing novel therapies like Barostim. He is a hands-on operational leader who has significant commercial and capital markets experience, and who is well known within the investment community. John’s experience driving growth while managing expenses is particularly relevant as we scale Barostim and reach more heart failure patients.

“I want to thank Jared for the significant impact he has had at the company since 2015. He led us through our IPO and helped build the financial foundation we stand on today,” Hykes added. “We’re grateful for his contributions and wish him success in his next chapter.”

Mr. Landry brings more than two decades of financial leadership experience in the medical device industry. He currently serves as CFO of Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), where he raised several rounds of capital and drove operational efficiencies to fund the company’s U.S. commercial expansion. Before that, he spent 12 years at Vapotherm, Inc. (formerly NYSE: VAPO), most recently as Senior Vice President and CFO, where he led the company’s IPO and built its finance, investor relations and public company reporting functions from the ground up. Earlier in his career, Mr. Landry held finance leadership roles at Salient Surgical Technologies (acquired by Medtronic in 2011), Bottomline Technologies, Hussey Seating Company and Coopers & Lybrand. He holds a B.S. in Accountancy from Bentley College, is a CPA (inactive) and serves on the board of Liberate Medical, Inc.

“Barostim is changing how physicians treat heart failure and the positive impact it is having on patients’ lives is what drew me to this role,” said John Landry. “I’ve spent most of my career in the medical device industry helping to build the infrastructure and operating discipline needed as companies scale their commercial efforts. I’m excited to join the CVRx team and see a real opportunity to bring that same operating discipline to support the business as we execute our commercial growth strategy.”

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

Experienced consumer financial services and product leaders will deepen member relationships and advance Oportun’s mission of expanding access to responsible financial services

SAN MATEO, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) — Oportun (Nasdaq: OPRT), a mission-driven financial services company, today announced that Bernardo Martinez has joined the Company as Chief Retail and Sales Officer and Garrett Hope has joined as Chief Product Officer.

Martinez will lead the functions that shape Oportun’s member experience across its digital, retail and contact center channels. Hope will lead product strategy and development, helping the Company deliver products and experiences that support members throughout their financial journey. Both executives will report to Doug Bland, Chief Executive Officer of Oportun.

“Bernardo and Garrett are accomplished leaders who understand how to build member-centered businesses and products at scale,” said Bland. “Their appointments round out the organizational changes we have made to position Oportun for its next phase of execution. Bernardo brings a deep understanding of the financial needs of consumers, while Garrett has led consumer product development across some of the world’s most recognized digital platforms. Together, they will help us deepen member relationships, sharpen our product focus, and deliver responsible financial products and experiences that support our members’ progress.”

Martinez brings more than 25 years of experience across consumer and small business financial services, lending, channel management and product development. Martinez was most recently at SoFi, where he led strategy, product development, and operations across the insurance, employee financial wellness platform, small business financial services, and consumer marketplace businesses. Prior to SoFi, Martinez led strategy, product development and operations for PayPal’s microbusiness and global merchant lending businesses. Martinez has also held leadership roles at Funding Circle, Banco del Progreso, and Bank of America.

“Oportun’s mission and its bilingual, omnichannel approach represent a unique opportunity to expand access to responsible financial services in the communities we serve,” said Martinez. “I am excited to join Doug and the team and to help make every interaction with Oportun responsive to the financial needs of our members.”

Hope brings 20 years of experience building consumer technology and marketplace products. Hope was most recently at PayPal, where he led end-to-end product development for consumer products and platforms, including the PayPal and Venmo apps. Prior to PayPal, Hope served in product leadership roles at Google and Expedia Group/Vrbo.

“Oportun has a meaningful opportunity to innovate its product set towards helping its members advance their financial goals,” said Hope. “I look forward to working with Doug and the leadership team to build simple and effective experiences that meet members where they are and enable informed financial decisions.”

About Oportun

Oportun (Nasdaq: OPRT) is a mission-driven financial services company that puts its members’ financial goals within reach. With intelligent borrowing, savings, and budgeting capabilities, Oportun empowers members with the confidence to build a better financial future. Since inception, Oportun has provided more than $22.7 billion in responsible and affordable credit, saved its members more than $2.5 billion in interest and fees, and helped its members set aside an average of more than $1,800 annually. For more information, visit oportun.com.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release, including statements regarding Oportun’s leadership team, strategy, member experience, product development, growth, execution, and future performance, are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include those risks described in Oportun’s filings with the Securities and Exchange. These forward-looking statements speak only as of the date on which they are made and, except to the extent required by federal securities laws, Oportun disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

Investor Contact
Dorian Hare
(650) 590-4323
ir@oportun.com

Media Contact
Michael Azzano
Cosmo PR for Oportun
michael@cosmo-pr.com
(415) 596-1978

Abivax Presents Business Updates and First Half 2026 Financial Results 

• Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and Controls (“CMC”), Quality and Information Technology (“IT”) functions
• Cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, combined with €767.1 million in net proceeds from the early July underwritten public offering, provides cash runway into Q4 2029
• Royalty certificates buy-back completed in Q2 2026 materially reduces royalty overhang, further strengthening Abivax’s debt-free financial position and flexibility to support future commercialization efforts

PARIS, France – September 21, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, reported today business updates and financial results for the six months ended June 30, 2026. The half-year financial statements, approved by the Company’s Board of Directors on September 18, 2026, have been reviewed by the Company’s statutory auditors, and the financial reports will be filed with the French and U.S. securities regulatory authorities on September 21, 2026. A brief presentation summarizing these business and financial updates is available on the Investor Relations section of Abivax’s website.

Strengthening Leadership Team Ahead of Potential Commercialization

Fabio Cataldi, M.D., Chief Medical Officer, will be leaving Abivax in the fourth quarter of 2026. Chris Rabbat, Ph.D., who has led Global Medical Affairs since 2023, will succeed Dr. Cataldi as Chief Medical Officer, leading the medical organization as Abivax advances toward potential commercialization. Dr. Rabbat brings extensive biopharmaceutical industry experience, including deep expertise in Inflammatory Bowel Disease (“IBD”) and experience supporting therapies through commercialization and launch. His combination of industry experience, therapeutic area expertise and commercial-stage medical leadership will be particularly valuable as Abivax prepares for the potential commercialization of obefazimod. Abivax thanks Dr. Cataldi for his important contributions to the Company, including his leadership through the late-stage development of obefazimod and advancement of the program toward its planned NDA submission.

Abivax has also appointed Tim Kelly as Chief Technical Officer. Mr. Kelly will lead the Company’s commercial CMC, Quality and Information Technology functions, further strengthening the infrastructure supporting Abivax’s continued growth and potential transition to a commercial-stage organization. Most recently, he served as Chief Technology Officer of Caribou Biosciences and previously was the CEO of Oxford Biomedica Solutions. He also held senior leadership roles at Homology Medicines, Shire, UCB Pharma and Biogen.

Both executive appointments are effective immediately.

“As we prepare Abivax for its next phase of growth and the potential commercialization of obefazimod, we are continuing to strengthen the leadership and capabilities needed to support that evolution,” said Marc de Garidel, MBA, Chief Executive Officer of Abivax. “We are deeply grateful to Fabio for his important contributions to Abivax and his leadership as we advanced obefazimod through late-stage development toward regulatory filing. Chris brings extensive experience in IBD and deep relationships with key opinion leaders, which will be critical as he leads our medical organization through the pre-commercial phase and toward potential commercialization. Tim brings extensive commercial supply, technical and operational experience that will further strengthen our CMC, Quality and IT capabilities as we prepare for potential commercialization.”

Abivax provided the following key updates on its business and operational goals in press releases published:

• On May 22, 2026, a press release titled “Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis”
• On June 1, 2026, a press release titled “Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis”
• On June 29, 2026, a press release titled “Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database”
• On July 6, 2026, Abivax completed its underwritten public offering of 7,360,000 American Depositary Shares, each representing one ordinary share, EUR 0.01 nominal value per share, of the Company, in the United States. The aggregate gross proceeds amounted to approximately $920 million, equivalent to approximately €807.4 million, before deduction of underwriting commissions and offering expenses, and the net proceeds, after deducting underwriting commissions and offering expenses, were approximately $874.1 million, equivalent to approximately €767.1 million.
• On July 23, 2026, a press release titled “Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments”

• On July 30, 2026, a press release titled “Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod”

First Half 2026 Financial Highlights

• Royalty Certificate Repurchase: On May 7, 2026, the Company completed the repurchase and cancellation of all outstanding royalty certificates for total consideration of $90 million (approximately €76.5 million), comprising $45 million in cash and $45 million in equity through the issuance of 403,347 ordinary shares represented by ADSs. The transaction resulted in an expense of approximately €43.2 million in the second quarter of 2026 and the derecognition of a €5.8 million deferred tax liability, with a corresponding tax benefit recognized for the six months ended June 30, 2026.
• Cash Position and Runway: The Company had cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, which, together with €767.1 million in net proceeds from the early July 2026 public offering, provides a projected cash runway into Q4 2029 based on current operating assumptions.
• R&D Expenses: Research and development (“R&D”) expenses increased by €29.9 million to €107.9 million (75.5% of operating expenses) in the first half of 2026 compared to €77.9 million (81.3% of operating expenses) in the first half of 2025. This increase was predominantly driven by:
  • A €6.8 million increase related to new indications (including combination therapy) for obefazimod;
  • A €4.6 million increase in transversal activities related to increased chemistry, manufacturing and controls and supply chain costs related to the progression of clinical trials and anticipation of potential future commercial launch;
  • A €6.3 million increase related to the Company’s Crohn’s disease (“CD”) clinical program, driven by the progression of Phase 2b clinical trials for obefazimod in CD; and
  • A €8.5 million increase related to the Company’s ulcerative colitis (“UC”) clinical program, driven by allocation of share-based compensation for grants awarded in 2025, partially offset by a decline in ABTECT clinical program costs as a result of 2025 milestone payments that did not occur in 2026.
• G&A Expenses: General and administrative expenses increased by €14.1 million to €30.4 million (21.3% of operating expenses) in the first half of 2026 compared to €16.3 million (17.0% of operating expenses) in the first half of 2025. This increase is primarily due to an increase of €8.6 million in personnel costs, primarily attributable to an increase in share-based compensation expense related to the impact of share-based awards granted in 2025 and their associated tax and social contributions of €6.1 million. The increase was also due to a €4.5 million increase in consulting and professional fees, driven by costs associated with building the Company’s infrastructure to support future growth in its operations.
• Sales and Marketing Expenses: Sales and marketing expenses increased by €3.1 million to €4.6 million (3.2% of operating expenses) in the first half of 2026 compared to €1.5 million (1.6% of operating expenses) in the first half of 2025. The increase was driven by costs related to the Company’s continued preparation for potential future sales and commercialization efforts for obefazimod in the U.S. which are expected to continue to accelerate in preparation for commercial launch.

Anticipated Upcoming Key Dates

• October 2026 – Participation at United European Gastroenterology Week (UEGW)
• End of 2026 – Planned NDA submission for obefazimod in UC
• Mid-2027 – Topline results from the Phase 2b ENHANCE-CD induction trial evaluating obefazimod in CD

First Half 2026 Financial Results (IFRS figures)

Statement of Cash Flows		For the six months ended June 30,
in millions of euros		2025		2026
Cash flows provided by (used in) operating activities		(66.6)		(102.5)
Cash flows provided by (used in) investing activities		1.3		1.5
Cash flows provided by (used in) financing activities		(16.6)		(39.3)
Effect of movements in exchange rates on cash held		(1.8)		6.2
Revaluation of cash equivalents measured at fair value		0.5		5.4
Increase (decrease) in cash and cash equivalents		(83.3)		(128.7)

Statement of Income (Loss)		For the six months ended June 30,
in millions of euros		2025		2026
Total operating income		2.1		2.5
Total operating expenses
of which Research and Development costs		(77.9)		(107.9)
of which Sales and Marketing costs		(1.5)		(4.6)
of which General and Administrative costs		(16.3)		(30.4)
Operating loss		(93.7)		(140.3)
Financial gain (loss)		(7.1)		(31.4)
Net loss before tax		(100.8)		(171.7)
Income tax		—		5.8
Net loss for the period		(100.8)		(165.9)

Statement of Financial Position		As of
in millions of euros		December 31, 2025		June 30, 2026
Non-current assets		33.1		34.6
Cash and cash equivalents		516.7		388.0
Other current assets1		34.6		39.6
Total Assets		584.3		462.2
Borrowings, notes and derivative instruments2		1.9		1.2
Royalty Certificates		30.2		—
Other non-current liabilities		35.3		24.1
Other current liabilities		61.7		70.6
Total Liabilities		129.1		95.9
Total Shareholders’ Equity		455.2		366.3
Total Liabilities and Shareholders’ Equity		584.3		462.2

¹ Includes certain short-term investments (terms of less than 12 months) of €14.4M, making total cash, cash equivalents and short-term investments of €402.4 million
² Includes both current and non-current portions of borrowings, convertible loan notes, derivative instruments, and lease liabilities

*****

About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contacts:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com   
+1 847 987 4878

Media Contacts:
LifeSci Communications
Karissa Cross, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business. Words such as “anticipate,” “expect,” “future,” “potential,” “will” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the potential therapeutic benefit of obefazimod, the expected timing for completion of the Phase 2b ENHANCE-CD induction trial of obefazimod and the availability and timing of results therefrom, the timing of regulatory filings including an NDA submission for obefazimod in UC, Abivax’s expectations for regulatory approval and commercialization of obefazimod for UC, the expected increase in costs associated with preparing for commercial launch of obefazimod, including the anticipated PDUFA date, Abivax’s cash runway, and other statements that are not historical fact. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission on March 23, 2026, under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

Attachment

• 20260921_Abivax_PR_First Half 2026 Financial Results

Combines critical photonics technologies with end-to-end assembly and test to deliver complete optical solutions for next-generation datacenters

SAXONBURG, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), the global leader in photonics, today announced PhotonLink™, an integrated optics platform that brings together Coherent’s broad portfolio of critical photonics technologies, precision assembly and test capabilities to deliver complete optical solutions for next-generation AI datacenters. The platform supports co-packaged optics (CPO), near-packaged optics (NPO) and emerging chip to chip connectivity.

As AI systems continue to scale, demand for higher bandwidth and lower power is driving optical connectivity closer to compute and switching silicon. These architectures require lasers, silicon photonics, precision optics, fibers and detectors to work together. PhotonLink brings those technologies and the expertise to integrate them into one platform.

“The next leap in AI requires more than faster chips – it requires a new way to connect them,” said Jim Anderson, Chief Executive Officer at Coherent. “Customers need complete optical solutions, not just individual components. Coherent is uniquely positioned to bring together the critical technologies, integrate and test the finished assemblies, and manufacture them at scale. PhotonLink puts that capability to work for the next generation of AI infrastructure.”

Coherent’s vertical integration spans compound semiconductor materials, lasers, optics and specialty fiber through final assembly and test. PhotonLink gives customers access to both individual components and complete optical assemblies from one partner, helping simplify system design, streamline qualification and reduce the complexity of integrating technologies from multiple suppliers.

FROM CRITICAL TECHNOLOGIES TO COMPLETE OPTICAL ASSEMBLIES

The PhotonLink platform spans four functions of the optical path: Generate, Shape, Guide and Receive. The portfolio includes indium phosphide (InP) lasers, vertical-cavity surface-emitting laser (VCSEL) arrays, silicon photonics, isolators, specialty fibers, micro-optics and detectors. Coherent integrates these technologies into external laser sources, precision fiber assemblies and optical modules tailored to customer architectures.

CUSTOMER ENGAGEMENT AND MANUFACTURING SCALE

Coherent has more than ten CPO customer engagements and more than ten NPO engagements, with anchor customers and long-term agreements secured for both architectures. The company also has more than five engagements in emerging chip to chip connectivity. Revenue from the PhotonLink platform is expected to begin ramping in Q4 of CY2026.

PhotonLink builds on Coherent’s established datacenter manufacturing base, which has shipped more than 300 million InP lasers and more than one billion InP and gallium arsenide (GaAs) photodetectors. Coherent is expanding its 6” InP and specialty fiber manufacturing capacity to support the PhotonLink ramp.

PHOTONLINK AT ECOC 2026
Coherent hosted a PhotonLink launch event on September 21 at the Gran Hotel Miramar in Málaga during the European Conference on Optical Communication (ECOC) 2026. The presentation and webcast recording are available at PHOTONLINK™ Launch webcast

Visitors to ECOC 2026 can also meet Coherent experts and explore PhotonLink at Stand 2100, Hall 2, at FYCMA – Trade Fair & Congress Center in Málaga, Spain.

For more information about PhotonLink, visit https://www.coherent.com/datacenter-communications/photonlink

About Coherent 
Coherent is the global photonics leader. We harness photons to drive innovation. Industry leaders in the datacenter, communications, and industrial markets rely on Coherent’s world-leading technology to fuel their own innovation and growth. Founded in 1971 and operating in more than 20 countries, Coherent brings the industry’s broadest, deepest technology stack; unmatched supply chain resilience; and global scale to help its customers solve their toughest technology challenges. For more information, visit coherent.com.

Media Contact: 
innovations@coherent.com 

RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 21, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee.

The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option award will vest over a four-year period, with 25% of the total shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, September 21, 2026, and 1/48th of the total shares underlying the award vesting following each one-month period thereafter, subject to continued service. The restricted stock unit award will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the award’s vesting commencement date, September 21, 2026, subject to continued service. The awards were granted as an inducement material to the new non-executive employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations

investorrelations@mineralystx.com

Source: Mineralys Therapeutics, Inc.

PERTH, Australia, Sept. 21, 2026 (GLOBE NEWSWIRE) — Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate presentation, now available on the Company’s website.

The new presentation outlines Novo’s strategic priorities, exploration results, project advancements, and near-term catalysts. It offers investors a clear and current view of Novo’s evolving growth strategy and its portfolio of high-potential gold assets.

“Our updated corporate presentation reflects the significant progress we’ve made across our exploration portfolio,” said Mr. Michael Spreadborough, Executive Co-Chairman and acting CEO of Novo Resources. “As we continue to unlock value across our projects, we remain focused on delivering disciplined growth and long-term value for shareholders.”

The presentation is available for download at: Novo Corporate Presentation

ABOUT NOVO

Novo is an Australian based gold explorer listed on the ASX and the TSX focussed on discovering standalone gold and copper projects with > 1 Moz Aueq development potential. Novo is an innovative gold explorer with a significant land package covering approximately 5,608 square kilometres in the Pilbara region of Western Australia, along with the 22 square kilometre Belltopper project in the Bendigo Tectonic Zone of Victoria, Australia. In addition to the above, Novo is part of two prospective farm in agreements in New South Wales.

Novo has a significant investment portfolio and a disciplined program in place to identify value accretive opportunities that will build further value for shareholders.

CONTACT

Investors: Mike Spreadborough +61 8 6400 6100 info@novoresources.com

North American Queries: Leo Karabelas +1 416 543 3120 leo@novoresources.com

Media: Peter Taylor +61 412 036 231 peter@nwrcommunication.com.au

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/660c418f-4111-417f-abad-9118ad04e0d8

https://www.globenewswire.com/NewsRoom/AttachmentNg/9971894d-1ed1-414a-95ad-5d5cc118b4db

JACKSONVILLE, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) — CSX Corp. (NASDAQ: CSX) will release third quarter financial and operating results after the market close on Wednesday, Oct. 21, 2026. This will be followed by a conference call and live webcast hosted by the company’s management team at 4:30 p.m. ET.

Those interested in participating via teleconference may dial 1-888-510-2008. Callers outside the U.S. may dial 1-646-960-0306. Participants should dial in 10 minutes prior to the call and use 3368220 as the passcode.

Presentation materials and access to the webcast will be available on the company’s website at investors.csx.com. Following the earnings call, a webcast replay will be archived on the company’s website.

About CSX

CSX, based in Jacksonville, Florida, is a premier transportation company. It provides rail, intermodal and rail-to-truck transload services and solutions to customers across a broad array of markets, including energy, industrial, construction, agricultural and consumer products. For nearly 200 years, CSX has played a critical role in the nation’s economic expansion and industrial development. Its network connects every major metropolitan area in the eastern United States, where nearly two-thirds of the nation’s population resides. It also connects approximately 250 short-line railroads and more than 70 ocean, river and lake ports with major population centers and farming towns alike. More information about CSX Corporation and its subsidiaries is available at www.csx.com. Like us on Facebook and follow us on X, formerly known as Twitter.

Contact:

Matthew Korn, CFA, Investor Relations
904-366-4515

Austin Staton, Corporate Communications
855-955-6397

VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:

• TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET

Details about the presentation, including webcast information, can be found on the Investors section of Xenon’s website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc. 

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K_V7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K_V7 and Na_V1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner. 

Contacts: 

For Investors:
Laura Perry/Emily Huang
Argot Partners
Xenon@argotpartners.com

For Media:  
Colleen Alabiso  
Senior Vice President, Corporate Affairs  
media@xenon-pharma.com  

MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced the closing of its previously announced indirect acquisition of M3 Wellness, a dispensary located in Hawthorne, Nevada, from M3 Wellness, LLC (“M3 Wellness”) pursuant to an asset purchase agreement entered on June 5, 2026 (the “Transaction”).

The total consideration for the Transaction was $500,000, $290,000 of which was settled in cash on the closing date, with the remaining $210,000 balance satisfied by the issuance of 13,888 subordinate voting shares of Vireo, at a deemed issue price per share of $15.12.

About Vireo Growth Inc.

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) is a leading vertically integrated cannabis company building a broad platform across cannabis and adjacent agricultural markets. The Company operates cultivation, manufacturing, retail dispensaries, home delivery, distribution, and agricultural supply businesses across the United States, creating exposure to both cannabis and complementary adjacent markets. With operations in 10 states and more than 170 dispensaries nationwide, Vireo combines disciplined capital allocation, strategic acquisitions, and local market execution to scale its platform and drive long-term shareholder value. The Company is focused on expanding market share and strengthening its portfolio of consumer brands and services, while supporting the customers, employees, shareholders, and communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Forward-Looking Information
This press release contains “forward-looking information” or “forward-looking statements” within the meaning of applicable United States and Canadian securities legislation (referred to herein as “forward-looking information”). Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding expectations around the Transaction and the expected benefits thereof. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release and are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q filed with the U.S. Securities Exchange Commission. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks and uncertainties associated with the Transaction, some of which are beyond the Company’s control; the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties as a result of the Transaction; the effects of the Transaction on the Company and the interests of various constituents; the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in its various markets; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission at www.sec.gov and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.com.

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

Contact Information:

Lynn Ricci
Director Investor Relations & Corporate Communications
investor@vireogrowth.com
(781) 956-7052